Takeda expects to record a provision of about JPY 402.5 billion (roughly $2.5 billion at prevailing exchange rates) related to an Amitiza antitrust verdict in the U.S.
A federal jury awarded $884.9 million in single damages to wholesalers and retailers in the Amitiza litigation, which is set to be tripled under U.S. antitrust law to nearly $2.5 billion.
Takeda has stated it will vigorously pursue post‑trial motions and appeal the verdict and will seek a stay of execution while the appeal proceeds.
The company is revising its FY2025 financial statements to reflect this provision as a subsequent event but indicates its FY2025 Core results and FY2026 financial forecast remain materially unchanged, except for potential impacts to adjusted free cash flow.
Sources:
Takeda is Living the Japanese Proverb: "Wasp stings a crying eye"
Takeda Provides an Update regarding Jury Verdict in AMITIZA ...
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury ...
Immunovant's potential autoimmune 'blockbuster'; Wave's RNA ...
Amitiza Direct Purchasers | Home
Takeda's VYVANSE Cliff: Why Japan's Pharma Giant Is Poised for a ...
Amitiza Direct Purchaser Antitrust Class-Action Litigation
Takeda faces USD 884943990 US antitrust verdict | TAK SEC Filing
Takeda Found Liable for Delaying Generic Constipation Drug ...
Takeda Pharma ordered to pay $2.5 billion in Amitiza case
Takeda Updates FY2025 Financial Results Based on ...
Jury Hits Takeda With $885 Million Antitrust Verdict
Japan's Takeda engaged in antitrust scheme to delay generic ...
Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict - Pharmaceutical Technology
Jury Verdict in AMITIZA Antitrust Litigation Targets Takeda - Panabee